Phase I/II Trial Of Intracerebral IL13-PE38QQR Infusions In Pediatric Patients With Recurrent Malignant Glioma.

Trial Profile

Phase I/II Trial Of Intracerebral IL13-PE38QQR Infusions In Pediatric Patients With Recurrent Malignant Glioma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Cintredekin besudotox (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 01 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov (NCT00378235).
    • 01 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov (NCT00378235).
    • 24 Apr 2011 Status changed from discontinued to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top